Get the Stockscreener App
0.00
100.00%
-15.02
Definium Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
See More
Previous Close:
$15.02
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.48B
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
0.00
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$15.29
Definium Therapeutics Inc Stock (MNMD) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Definium Therapeutics Inc
|
0.00 | 1.48B | 11.40B | -95.73M | -64.37M | -2.45 |
VRTX
Vertex Pharmaceuticals Inc
|
436.94 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
744.29 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
795.51 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.21 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
311.22 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-10-26 | Initiated | Piper Sandler | Overweight |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-30-26 | Initiated | Jefferies | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (MNMD) Latest News
DFTX Maintained by Leerink Partners -- Price Target Raised to $3 - GuruFocus
DFTX News Today | Why did Definium Therapeutics stock go up today? - MarketBeat
Definium Therapeutics (DFTX) Stock Gains After Hours: Here's What's Driving The Move - Benzinga
Definium Therapeutics Announces New Employee Inducement GrantsApril 20, 2026 - BioSpace
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $38 - Moomoo
Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst - MSN
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump’s Psychedelic Research Order - MEXC Exchange
Definium Therapeutics stock hits 52-week high at 25.63 USD - Investing.com
Definium Therapeutics (DFTX) Stock Hits 52-Week High as Trump Backs Psychedelic Medicine Research - CoinCentral
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump's Psychedelic Research Order - Blockonomi
Psychedelic Pharmaceutical Companies' Shares Rise Following Executive Order -- Update - Moomoo
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? - Benzinga
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - Seeking Alpha
Psychedelic drug makers rally as Trump orders FDA to expedite reviews - Yahoo Finance
Psychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gains - Seeking Alpha
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics (DFTX) Is Up 5.3% After White House Signals Support For Psychedelic Research - simplywall.st
Definium Therapeutics (DFTX) Stock Climbs Following White House Psychedelic Policy Shift - MEXC
Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments | MEXC News - MEXC Exchange
Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments - MEXC
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics supports White House executive order on mental health innovation, committed to developing psychedelic treatments for mental health - marketscreener.com
Definium Therapeutics Supports White House Executive Order On Mental Health Innovation, Committed To Developing Psychedelic Treatments For Mental Health - TradingView
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments - The Joplin Globe
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026 - TechStock²
Trump signs executive order on psychedelics (ATAI:NASDAQ) - Seeking Alpha
Trump Trade: President to sign order on psychedelic used for PTSD - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? - Yahoo Finance
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones (NASDAQ:DFTX) - Seeking Alpha
DFTX Initiates Coverage On Stifel -- Rating Set to Buy - GuruFocus
Can an LSD candidate do for anxiety what Spravato did for depression? - Pharma Voice
Stifel Initiates Definium Therapeutics at Buy With $30 Price Target - marketscreener.com
Definium Therapeutics Conference Slot Tests Psychedelic Phase III And Funding Story - Sahm
DFTX Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
Stifel initiates Definium stock with buy rating on anxiety drug - Investing.com UK
Stifel initiates Definium stock with buy rating on anxiety drug By Investing.com - Investing.com Australia
Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data - MarketBeat
Definium Therapeutics Price Target Raised to $38.00/Share From $25.00 by Canaccord Genuity - Moomoo
Shroom stocks rise as Trump is said to sign executive order on psychedelic drug - Seeking Alpha
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year HighStill a Buy? - MarketBeat
DFTX Options Chain — NASDAQ:DFTX - TradingView
DFTX Options Volatility — NASDAQ:DFTX - TradingView
Definium Therapeutics Sees Insider Stock Selling - 富途牛牛
DFTX: Definium Therapeutics, Inc.Income Statment - Zacks Investment Research
All News for DFTX : Definium Therapeutics, Inc. - Zacks Investment Research
DFTX: Piper Sandler Initiates Coverage with Overweight Rating | - GuruFocus
Definium Therapeutics stock hits 52-week high at 21.99 USD - Investing.com
Definium Therapeutics stock hits 52-week high at 21.99 USD By Investing.com - Investing.com UK
Definium Therapeutics Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Definium Therapeutics Inc Stock (MNMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer |
Mar 25 '26 |
Sale |
18.47 |
10,702 |
197,666 |
271,079 |
| Barrow Robert | Chief Executive Officer |
Mar 25 '26 |
Sale |
18.47 |
24,431 |
451,241 |
752,454 |
1.23%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):